Johnson & Johnson (JNJ) Shares Sold by Gilman Hill Asset Management LLC
Gilman Hill Asset Management LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 11.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,230 shares of the company’s stock after selling 1,775 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in Johnson & Johnson were worth $1,750,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Lynch & Associates IN lifted its holdings in shares of Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after buying an additional 841 shares during the period. Oakbrook Investments LLC lifted its holdings in shares of Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after purchasing an additional 9,375 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Johnson & Johnson during the first quarter valued at $1,731,000. Bollard Group LLC lifted its holdings in shares of Johnson & Johnson by 5.0% during the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock valued at $1,263,000 after purchasing an additional 459 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. lifted its holdings in shares of Johnson & Johnson by 278.0% during the second quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock valued at $32,001,000 after purchasing an additional 177,900 shares during the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.02% on Friday, reaching $133.22. The company’s stock had a trading volume of 3,024,247 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The stock has a market cap of $357.56 billion, a PE ratio of 22.39 and a beta of 0.78. The company’s 50 day moving average is $132.23 and its 200-day moving average is $129.87.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.74 earnings per share. On average, equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
JNJ has been the subject of several analyst reports. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $128.00 target price on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a report on Friday, July 21st. Jefferies Group LLC reaffirmed a “hold” rating and set a $145.00 target price (up from $140.00) on shares of Johnson & Johnson in a report on Friday, July 14th. Finally, Citigroup Inc. initiated coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 target price for the company. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $134.79.
WARNING: “Johnson & Johnson (JNJ) Shares Sold by Gilman Hill Asset Management LLC” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-sold-by-gilman-hill-asset-management-llc/1618279.html.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.